1. Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Meta-Analysis of Colorectal Cancer Survival Data
   Yao Chen et al, 2012, The International Journal of Biological Markers CrossRef
2. Gender-dependent association ofTYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity
   Charalampia Ioannou et al, 2021, Pharmacogenomics CrossRef
3. Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy
   L Benhaim et al, 2014, The Pharmacogenomics Journal CrossRef
4. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy
   Elena De Mattia et al, 2015, Drug Resistance Updates CrossRef
5. Thymidylate synthase gene polymorphisms as important contributors affecting hepatocellular carcinoma prognosis
   X. Wang et al, 2017, Clinics and Research in Hepatology and Gastroenterology CrossRef
6. Association of Thymidylate Synthase and Hypoxia Inducible Factor-1alpha DNA Polymorphisms with Pancreatic Cancer
   Jaime Ruiz-Tovar et al, 2012, Tumori Journal CrossRef
7. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers
   Alessia Bignucolo et al, 2022, Expert Review of Clinical Pharmacology CrossRef
8. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer
   Shoaib Afzal et al, 2011, Pharmacogenomics CrossRef
9. Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines
   Barbara A. Jennings et al, 2013, PLoS ONE CrossRef
10. An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens
    Ying-Chao Wang et al, 2013, Molecular Biology Reports CrossRef